- Home
- SNX vs BBIO Comparison
SNX vs BBIO Comparison
Compare SNX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNX
- BBIO
- Stock Information
- Founded
- SNX 1980
- BBIO 2015
- Country
- SNX United States
- BBIO United States
- Employees
- SNX N/A
- BBIO N/A
- Industry
- SNX Retail: Computer Software & Peripheral Equipment
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNX Technology
- BBIO Health Care
- Exchange
- SNX Nasdaq
- BBIO Nasdaq
- Market Cap
- SNX N/A
- BBIO 6.7B
- IPO Year
- SNX 2003
- BBIO 2019
- Fundamental
- Price
- SNX $118.18
- BBIO $34.67
- Analyst Decision
- SNX Strong Buy
- BBIO Strong Buy
- Analyst Count
- SNX 9
- BBIO 12
- Target Price
- SNX $137.22
- BBIO $57.09
- AVG Volume (30 Days)
- SNX 789.8K
- BBIO 3.2M
- Earning Date
- SNX 06-24-2025
- BBIO 04-29-2025
- Dividend Yield
- SNX 1.49%
- BBIO N/A
- EPS Growth
- SNX 16.43
- BBIO N/A
- EPS
- SNX 8.00
- BBIO N/A
- Revenue
- SNX $59,008,890,000.00
- BBIO $127,415,000.00
- Revenue This Year
- SNX $3.20
- BBIO $13.67
- Revenue Next Year
- SNX $4.26
- BBIO $118.02
- P/E Ratio
- SNX $14.42
- BBIO N/A
- Revenue Growth
- SNX 4.62
- BBIO N/A
- 52 Week Low
- SNX $92.23
- BBIO $21.62
- 52 Week High
- SNX $145.10
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- SNX 63.60
- BBIO 49.67
- Support Level
- SNX $112.27
- BBIO $33.92
- Resistance Level
- SNX $115.71
- BBIO $39.16
- Average True Range (ATR)
- SNX 2.42
- BBIO 1.43
- MACD
- SNX 1.77
- BBIO -0.16
- Stochastic Oscillator
- SNX 97.57
- BBIO 31.05
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.